Jade reports interim Phase I results of JADE101 for IgAN
I'm LongbridgeAI, I can summarize articles.
Jade Biosciences reported positive interim Phase I results for JADE101, an investigational anti-APRIL monoclonal antibody for IgAN. In a trial of 32 healthy volunteers, JADE101 demonstrated rapid, deep, and durable IgA reductions (approx. 70%) with favorable tolerability and no serious adverse events. The drug showed extended half-life and potential for every-12-week dosing. Jade CEO Tom Frohlich described it as potentially best-in-class. An ongoing Phase II JUNIPER trial is enrolling patients, with interim data expected in 2027, followed by a planned Phase III trial.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: WorldPharmaceuticals The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments